검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous Natural Killer Cell Therapy (Autologous Natural Killer Cell Therapy) Vaxcell Bio, Co., Ltd.·Hepatocellular Carcinoma ORR 14% |
|---|---|
Overview Program | Autologous Natural Killer Cell Therapy |
Overview Company | Vaxcell Bio, Co., Ltd. |
Overview Modality | CGT |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targeting both CAR antigen |
MoA Biomarker | PD-1 antibody plus P-GEMOX follow |
PK/PD Species | Mouse, vivo MPM xenograft |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, vivo MPM xenograft |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Methotrexate-induced myelopathy: a great imitator of relapsed malignant lymphoma.. Methotrexate-induced myelopathy is a rare adverse effect of intrathecal methotrexate, characterized by acute or subacute myelopathy-like neurological manifestations and magnetic resonance imaging findings resembling subacute combined degeneration. Because neurological symptoms often precede radiological abnormalitie… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 14% |
Clinical ORR | 14% |
Clinical PFS | 5.7 |
Clinical OS | 25.9 |
Clinical Result source | ClinicalTrials.gov NCT04011033 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous Natural Killer Cell Therapy (Autologous Natural Killer Cell Therapy) Vaxcell Bio, Co., Ltd.·Hepatocellular Carcinoma ORR 14% |
|---|---|
Overview Program | Autologous Natural Killer Cell Therapy |
Overview Company | Vaxcell Bio, Co., Ltd. |
Overview Modality | CGT |
Overview Target | Hepatocellular Carcinoma |
Overview Indication | Hepatocellular Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | targeting both CAR antigen |
MoA Biomarker | PD-1 antibody plus P-GEMOX follow |
PK/PD Species | Mouse, vivo MPM xenograft |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, vivo MPM xenograft |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Methotrexate-induced myelopathy: a great imitator of relapsed malignant lymphoma.. Methotrexate-induced myelopathy is a rare adverse effect of intrathecal methotrexate, characterized by acute or subacute myelopathy-like neurological manifestations and magnetic resonance imaging findings resembling subacute combined degeneration. Because neurological symptoms often precede radiological abnormalitie… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 14% |
Clinical ORR | 14% |
Clinical PFS | 5.7 |
Clinical OS | 25.9 |
Clinical Result source | ClinicalTrials.gov NCT04011033 |
Clinical Data Tier / Score | A · 43 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교